Merck & Co., Inc. (NYSE:MRK) known as MSD outside the United States and Canada, on 13 June announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes in real-world settings over three years. The registry is part of Merck’s new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. The research initiative and the new registry reflect Merck’s broader commitment to generate real-world evidence to help advance diabetes care. Merck & Co., Inc. (NYSE:MRK) net profit margin is 14.00% and weekly performance is 0.02%. On last trading day company shares ended up $58.06. Analysts mean target price for the company is $59.65. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 2.58%.
Pfizer Inc. (NYSE:PFE) and rival Swiss drugmaker Novartis AG on Tuesday said they had asked U.S. regulators to approve their vaccines to prevent meningitis infections in people aged 10 to 25. Pfizer Inc. (NYSE:PFE) shares fell -0.44% in last trading session and ended the day on $29.48. PFE gross Margin is 81.90% and its return on assets is 23.50%.Pfizer Inc. (NYSE:PFE) quarterly performance is -6.86%.
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) has been a bit up and down of late, which is perhaps fitting for a business buoyed by the male libido. The Chesterbrook-based drug company, which trades in testosterone and other solutions to male sexual dysfunction, had a net loss of $32.9 million in 2011, a profit of $85.9 million in 2012, a loss of $68 million last year. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) shares moved up 1.54% in last trading session and was closed at $21.78, while trading in range of $21.25 – $21.96. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) year to date (YTD) performance is 5.07%.
AstraZeneca PLC(ADR) (NYSE:AZN) heartburn drug Nexium is the most recent big drug to face delays to its generic version. Key patents on the U.K. Company’s “purple pill,” which ranks among the world’s best-selling prescription drugs, expired at the end of May, but manufacturing problems at India’s Ranbaxy Laboratories Ltd. have prevented the launch of an expected generic rival. AstraZeneca plc (ADR) (NYSE:AZN) ended the last trading day at $73.94. Company weekly volatility is calculated as 1.27% and price to cash ratio as 18.10.AstraZeneca plc (ADR) (NYSE:AZN) showed a positive weekly performance of 1.57%.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:LLY) announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA). Eli Lilly and Co (NYSE:LLY) net profit margin is 17.40% and weekly performance is -0.84%. On last trading day company shares ended up $59.25. Analysts mean target price for the company is $60.88. Eli Lilly and Co (NYSE:LLY) distance from 50-day simple moving average (SMA50) is 0.33%.
Leave a Reply